Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188689 · ClinicalTrials.gov registry record · NA
Evaluation of A Clinical Diagnostic Test for CRDS
A NA study of Calcium Release Deficiency Syndrome (CRDS), sponsored by Population Health Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 18
- Study locations
NCT06188689: Recruiting NA study of Calcium Release Deficiency Syndrome (CRDS), sponsored by Population Health Research Institute.
NCT06188689 is a NA study of Calcium Release Deficiency Syndrome (CRDS) that is actively recruiting participants, run by Population Health Research Institute. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06188689, a NA study of Calcium Release Deficiency Syndrome (CRDS), is actively recruiting participants, sponsored by Population Health Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 18
- Study locations
Study Summary
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Primary Outcome
T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Pacing
Study Locations (18)
Ontario
- Hamilton General Hospital - Hamilton
- London Health Sciences Centre - University Hospital - London
- Ottawa Heart Institute - Ottawa
- Toronto General Hospital - Toronto
Other
- Universitair Ziekenhuis Brussel - Brussels
- Aarhus University Hospital - Aarhus
- Shaare Zedek Medical Center - Jerusalem
British Columbia
- Children's & Women's Health Centre of British Columbia - Vancouver
- The University of British Columbia - Vancouver
Quebec
- Montréal Heart Institute - Montreal
- Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval - Québec
California
- University of California - San Francisco
Minnesota
- Mayo Clinic - Rochester
Washington
- University of Washington - Seattle
Antwerp
- Antwerp University Hospital - Edegem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT06188689 shows while recruiting
NCT06188689 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Calcium Release Deficiency Syndrome (CRDS) appearing as the primary indexed condition, and to 1 intervention - of which Pacing is the first listed.
NCT06188689 lists 18 locations in 11 states (Ontario, Other, British Columbia).
Frequently Asked Questions
What is clinical trial NCT06188689 about?
NCT06188689 is a clinical study titled "Evaluation of A Clinical Diagnostic Test for CRDS". Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize t...
What is the current status of trial NCT06188689?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-02-02. Estimated completion is 2026-03.
What conditions does trial NCT06188689 study?
This clinical trial studies the following conditions: Calcium Release Deficiency Syndrome (CRDS).
What interventions are being tested in trial NCT06188689?
The interventions under investigation include: Pacing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06188689?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188689 being conducted?
This trial has 18 study locations across California, Minnesota, Washington, Antwerp, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06188689's enrollment target sits among peer trials
400 246th of 2000 higher than 1,734 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI